![]() |
Clinical Practice Guideline: Report of the Recommendations, Communication Disorders, Assessment and Intervention for Young Children (Age 0-3 years) |
|
Return to Early Intervention Index |
Purpose of Clinical Practice Guidelines for Children with Developmental Disabilities
This clinical practice guideline on communication disorders is intended to provide parents, professionals, and others with recommendations based on the best scientific evidence available about "best practices" for assessment and intervention for young children with communication disorders.
| <The guideline recommendations suggest "best practices", not policy or regulation |
This clinical practice guideline provides recommendations about best practices for assessment and intervention for young children with communication disorders, with a primary focus on children under 3 years of age. However, age 3 is not an absolute cut-off, and many of the recommendations in this guideline are also applicable in somewhat older children.
The primary focus of the recommendations in this guideline is:
The guideline panel agreed on an operational definition of communication disorders for use in this guideline. However, before providing the operational definition as used in this guideline, it is helpful to review a generally accepted standard definition of communication disorder.
As defined by the American Speech-Language-Hearing Association (ASHA), a communication disorder is:
"An impairment in the ability to receive, send, process, and comprehend concepts or verbal, nonverbal and graphic symbol systems. A communication disorder may be evident in the processes of hearing, language, and/or speech. A communication disorder may range in severity from mild to profound. It may be developmental or acquired. Individuals may demonstrate one or any combination of the three aspects of communication disorders. A communication disorder may result in a primary disability or it may be secondary to other disabilities" (ASHA, 1993).
<How the term "communication disorders" is used in this guideline
The ASHA definition above encompasses children with a delay or deviation in speech, language, and/or hearing. In this guideline<, the term "communication disorders" is used to refer primarily to speech and language problems rather than hearing problems. Although hearing disorders are an important type of communication disorder in young children, assessment and intervention for hearing problems is not a primary focus of this guideline.
In the literature on communication disorders in young children, varying definitions are sometimes used for the terms "disorder" and "delay," as they refer to communication problems. A variety of different diagnostic terms and labels are also used to describe specific communication problems in young children. At the current time, there is not a standard definition of these various terms used by all professionals dealing with young children. For this reason, these terms are operationally defined for use in this guideline as follows:
Definitions are given below for some major terms as they are used in this guideline.
| Assessment | The entire process of evaluating the child, including the activities and tools used to measure level of functioning, establish eligibility for services, determine a diagnosis, plan intervention, and measure treatment outcomes. |
| Family | The child's primary caregivers, which might include one or both parents, siblings, grandparents, foster care parents, or others usually in the child's home environment(s). |
| Parents | The primary caregiver(s) or other person(s) who has (have) significant responsibility for the welfare of the child. |
| Professional | Any provider of professional services who is qualified to provide the intended service. Qualifications generally include training, experience, licensure, and/or other state requirements. The term is not intended to imply any specific professional degree or qualifications other than appropriate training and credentials. (It is beyond the scope of this guideline to address professional practice issues.) |
| Screening | May be used in the early stages of the assessment process to identify children who need more in-depth evaluation. Screening may include parent interviews or written questionnaires, observation of the child, or use of specific screening tests. |
| Target Population | A study group selected according to specific characteristics. For this guideline, the target population is children with possible communication disorders from birth to age 3 years. Throughout this document, the term young children is used to describe this target age group. |
| Young Children | Term used in this guideline to describe the target age group (children from birth to age 3 years.) Although children from birth to age 3 is the intended focus of the guideline, the term young children may also include somewhat older children. |
Every professional discipline today is being called upon to document its effectiveness. Current questions often asked of professionals are:
The difficulty in answering these questions is that many times the methods used in current professional practice have not been studied extensively or rigorously.
Evidence-based clinical practice guidelines are intended to help professionals, parents, and others learn what scientific evidence exists about the effectiveness of specific clinical methods. This information can be used as the basis for informed decisions. This guideline represents the panel's concerted attempt to interpret the available scientific evidence in a systematic and unbiased fashion and to use this as the basis for developing guideline recommendations. It is hoped that, by using this process, the guideline provides a set of recommendations that reflects current best practices and will lead to optimal outcomes for children with developmental problems.
Each of the guideline recommendations in Chapters III and IV is followed by a "strength of evidence" rating designated by the letter [A], [B], [C], [D1], or [D2] in brackets immediately after the recommendation. These strength of evidence ratings indicate the amount, general quality, and clinical applicability (to the guideline topic) of scientific evidence used as the basis for each guideline recommendation.
| Evidence Ratings: [A] = Strong [B] = Moderate [C] = Limited [D1] = No evidence meeting criteria [D2] = Literature not reviewed |
[A] =
[B] = [C] = [D] = [D1] = [D2] = The strength of evidence rating does
not indicate whether the recommendation is for or against use of a
method. For example: In developing evidence-based
clinical practice guidelines, the process of reviewing the
scientific literature to find evidence-based answers to specific
clinical questions is challenging. Many times the specific clinical
issue of interest may not have been studied extensively in
well-designed studies of the type that can adequately determine if
a clinical method is effective. At other times, even when
well-designed studies have been done on a particular clinical
topic, the study findings themselves seldom present totally
straightforward and unambiguous answers to the clinical questions
of interest. Careful analysis of the studies and
considerable judgment are always needed when using the findings of
research studies to help in making informed clinical decisions and
developing clinical practice guidelines. For most clinical topics,
it is exceptional to find studies that evaluate exactly the
clinical situations and types of subjects that are of interest.
Therefore, it is almost always necessary to generalize to some
extent in terms of the subject characteristics (such as age or IQ)
and the clinical setting or the type of assessment or intervention
method used. The research studies reviewed for this guideline were
no exception. In using research evidence to help
make clinical decisions, the two primary considerations are the quality of the evidence and its clinical applicability to the question of interest. Primary Considerations in Using Research Evidence The overall usefulness of a study's
findings to clinical decision-making relates both to confidence in
the results (based on the quality and amount of scientific
evidence) and the similarity of the study's subjects, clinical
methods, and setting to the question of interest (that is, its
applicability). Considerations about quality of studies The considerations about using
scientific evidence as the basis for clinical decisions apply to
all the recommendations in this guideline. For some of the clinical
questions of interest, several studies were found that met criteria
for adequate evidence about efficacy. For other questions of
interest, few or no studies were found that met such
criteria. There are also numerous articles in
the scientific literature that did not meet criteria for adequate
evidence about efficacy, yet still contained valuable information
that may be useful in clinical practice. These articles include
case reports, case series (sometimes using pre and post-test
designs), and other descriptive studies, as well as articles that
primarily discuss theory or opinion. Relatively rigorous criteria were
used for selecting studies that would provide adequate evidence
about efficacy. The findings of these studies were used as the
primary basis for developing guideline recommendations. In many
cases, information from the articles and studies not meeting these
evidence criteria was also reviewed by the panel, but information
from these sources was not considered evidence about efficacy and
was not given as much weight in making guideline recommendations. Considerations about applicability of studies Of particular concern for this
guideline was finding high-quality scientific studies that focused
on children under the age of 3 years. For some topics, studies were
found that evaluated only children within the guideline's target
population (children from birth to 3 years of age), but for other
topics, the only studies found evaluated groups that included
somewhat older children (over age 3). As noted above, the inclusion of
children over age 3 does not affect the quality of the study or
bias the results, but it may make the study's findings somewhat
less applicable to the guideline topic. Ratings of applicability
for this guideline are described in Appendix A, Table
A-6. Applicability was taken into account
when making guideline recommendations and more weight was given to
findings from high-quality studies that focused on children under 3
years old. However, when there were few good studies found that
focused on children in the target age group, then the panel thought
it important to generalize from evidence found in good studies of
somewhat older children. Judging the quality and applicability of the evidence when making guideline recommendations Given the considerations above, the
panel needed to carefully evaluate the quality and applicability of
the scientific evidence that was used as the basis for these
guideline recommendations. Similar limitations and considerations
apply to all evidence-based practice guidelines. The strength of
evidence ratings are a reflection of both the amount and quality of
the scientific evidence found and its applicability to the
guideline topic. Additional information about
reviewing and rating the evidence used to develop the guideline
recommendations can be found in the methodology tables in Appendix
A. It is intended that this DOH
Clinical Practice Guideline for developmental disabilities in
children from birth to age 3 be a dynamic document that is updated
periodically as new scientific information becomes available. This
guideline reflects the state of knowledge at the time of
publication, but, given the inevitable evolution of scientific
information and technology, it is the intention of the DOH that
periodic review, updating, and revision will be incorporated into
an ongoing guideline development process. There are three versions of this
clinical practice guideline published by the Department of Health.
All versions of the guideline contain the same basic
recommendations specific to the assessment and intervention methods
evaluated by the panel, but with different levels of detail
describing the methods and the evidence that supports the
recommendations. The three versions are:

Send questions or comments to: bei@health.state.ny.us
Revised: June 2002